Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 5:15:1396642.
doi: 10.3389/fneur.2024.1396642. eCollection 2024.

Guillain-Barre syndrome and link with COVID-19 infection and vaccination: a review of literature

Affiliations
Review

Guillain-Barre syndrome and link with COVID-19 infection and vaccination: a review of literature

Vijaya Lakshmi Valaparla et al. Front Neurol. .

Abstract

Background: Guillain-Barré syndrome (GBS) is an autoimmune disease associated with significant morbidity. A wide variety of infectious and non-infectious triggers have been identified to be associated with GBS. COVID-19 has gained attention in recent years for its role in GBS pathogenesis. Our study aims to review the literature on GBS and its epidemiological and pathophysiological association with COVID-19.

Description: Recent literature on GBS associated with COVID-19 infections, such as case reports, case series, systematic reviews, and large-scale epidemiological studies, were reviewed. We also reviewed studies that included vaccines against COVID-19 in association with GBS. Studies that focused on understanding the pathobiology of GBS and its association with infectious agents including COVID-19 were reviewed.

Conclusion: Despite a lack of consensus, GBS is strongly associated with COVID-19 infection. The exact pathophysiological mechanism regarding COVID-19 as a causative agent of GBS is unknown. Mechanisms, such as the proinflammatory state, triggering of autoimmunity, and direct viral invasion, are postulated and remain to be investigated. Adenovirus vector vaccines are most likely associated with GBS, and the consensual reports clearly suggest mRNA vaccines are associated with low risk and may be protective against GBS by reducing the risk of COVID-19 infection.

Keywords: COVID-19; COVID-19 vaccine; Guillain–Barre Syndrome (GBS); autoimmune disease; peripheral nervous system.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Pathophysiology of COVID-19 related GBS – schematic. The three pathophysiological mechanisms for GBS associated with COVID-19 infections. Left to right: direct invasion by the virus via ACE2 receptors in the central and peripheral nervous system causing direct toxicity in cases touted to be para-infectious forms of GBS. COVID-19 infections causing a cytokine storm due to markedly elevated levels of several proinflammatory mediators, the most prominent being TNF-α, which leads to complement activation, causing macrophage-lead myelin damage, and IL-17, which directly causes Schwann cell degeneration. Both SARS-CoV-2 and adenovirus vector vaccines cause humoral-mediated autoantibody formations such as GM1, GD1a, GD1b, GQ1b, and GT1b that target gangliosides on the nervous tissue, causing disruption of anatomical and physiological barriers with three main targets on nerves: 1. Axon; 2. nodes of Ranvier; and 3. Myelin.

Similar articles

Cited by

References

    1. Laman JD, Huizinga R, Boons GJ, Jacobs BC. Guillain-Barré syndrome: expanding the concept of molecular mimicry. Trends Immunol. (2022) 43:296–308. 10.1016/j.it.2022.02.003 - DOI - PMC - PubMed
    1. Guillain MG, Barré J, Strohl A. On a radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Remarks on clinical and graphical character of tendon reflexes. Ann Med Interne (Paris). (1999) 150:24–32. - PubMed
    1. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. (2021) 397:1214–28. 10.1016/S0140-6736(21)00517-1 - DOI - PubMed
    1. Palaiodimou L, Stefanou MI, Katsanos AH, Fragkou PC, Papadopoulou M, Moschovos C, et al. . Prevalence, clinical characteristics and outcomes of Guillain– Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. (2021) 28:3517–29. 10.1111/ene.14860 - DOI - PMC - PubMed
    1. Tatu L, Nono S, Grácio S, Koçer S. Guillain–Barré syndrome in the COVID-19 era: another occasional cluster? J Neurol. (2021) 268:1198–200. 10.1007/s00415-020-10005-3 - DOI - PMC - PubMed

LinkOut - more resources